Meyka Pro banner
Zai Lab Limited

Zai Lab Limited Fundamental Analysis

9688.HKHKSE
HealthcareBiotechnology
HK$16.03
HK$0.11(0.69%)
Hong Kong Market opens in 16h 22m

Zai Lab Limited Fundamental Analysis

Zai Lab Limited (9688.HK) shows weak financial fundamentals with a PE ratio of -12.51, profit margin of -39.29%, and ROE of -24.29%. The company generates $0.5B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio-0.48
Current Ratio2.40

Areas of Concern

ROE-24.29%
Operating Margin-53.49%
Cash Position4.27%
We analyze 9688.HK's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -34.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-34.3/100

We analyze 9688.HK's fundamental strength across five key dimensions:

Efficiency Score

Weak

9688.HK struggles to generate sufficient returns from assets.

ROA > 10%
-16.23%

Valuation Score

Excellent

9688.HK trades at attractive valuation levels.

PE < 25
-12.51
PEG Ratio < 2
-0.48

Growth Score

Weak

9688.HK faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Excellent

9688.HK maintains a strong and stable balance sheet.

Debt/Equity < 1
0.35
Current Ratio > 1
2.40

Profitability Score

Weak

9688.HK struggles to sustain strong margins.

ROE > 15%
-2429.46%
Net Margin ≥ 15%
-39.29%
Positive Free Cash Flow
No

Key Financial Metrics

Is 9688.HK Expensive or Cheap?

P/E Ratio

9688.HK trades at -12.51 times earnings. This suggests potential undervaluation.

-12.51

PEG Ratio

When adjusting for growth, 9688.HK's PEG of -0.48 indicates potential undervaluation.

-0.48

Price to Book

The market values Zai Lab Limited at 3.44 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

3.44

EV/EBITDA

Enterprise value stands at -14.67 times EBITDA. This is generally considered low.

-14.67

How Well Does 9688.HK Make Money?

Net Profit Margin

For every $100 in sales, Zai Lab Limited keeps $-39.29 as profit after all expenses.

-39.29%

Operating Margin

Core operations generate -53.49 in profit for every $100 in revenue, before interest and taxes.

-53.49%

ROE

Management delivers $-24.29 in profit for every $100 of shareholder equity.

-24.29%

ROA

Zai Lab Limited generates $-16.23 in profit for every $100 in assets, demonstrating efficient asset deployment.

-16.23%

Following the Money - Real Cash Generation

Operating Cash Flow

Zai Lab Limited generates limited operating cash flow of $-96.82M, signaling weaker underlying cash strength.

$-96.82M

Free Cash Flow

Zai Lab Limited generates weak or negative free cash flow of $-107.15M, restricting financial flexibility.

$-107.15M

FCF Per Share

Each share generates $-0.09 in free cash annually.

$-0.09

FCF Yield

9688.HK converts -4.53% of its market value into free cash.

-4.53%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-12.51

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.48

vs 25 benchmark

P/B Ratio

Price to book value ratio

3.44

vs 25 benchmark

P/S Ratio

Price to sales ratio

5.13

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.35

vs 25 benchmark

Current Ratio

Current assets to current liabilities

2.40

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.24

vs 25 benchmark

ROA

Return on assets percentage

-0.16

vs 25 benchmark

ROCE

Return on capital employed

-0.34

vs 25 benchmark

How 9688.HK Stacks Against Its Sector Peers

Metric9688.HK ValueSector AveragePerformance
P/E Ratio-12.5129.15 Better (Cheaper)
ROE-24.29%438.00% Weak
Net Margin-39.29%-11409.00% (disorted) Weak
Debt/Equity0.350.78 Strong (Low Leverage)
Current Ratio2.405.14 Strong Liquidity
ROA-16.23%-21.00% (disorted) Weak

9688.HK outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Zai Lab Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ